AtaiBeckley clears U.S. antitrust review, but Lilly deal still awaits Australia

The merger was already the market’s baseline, so this is a process update rather than a new deal thesis. AtaiBeckley had previously disclosed the July 15, 2026 merger agreement with Eli Lilly, making regulatory progress partly known rather than a fresh strategic surprise. (Merger Agreement) 〔0〕

The U.S. antitrust hurdle is now cleared. The Hart-Scott-Rodino waiting period expired on August 28, removing one closing condition and modestly reducing execution risk. (U.S. Antitrust Review) 〔1〕

Foreign review is also progressing, but the deal is not fully cleared. The U.K. competition authority indicated it had no further questions at that time, while Australia determined the merger may proceed only after a 14-calendar-day waiting period. (Other Regulatory Reviews) 〔2〕

Net read: neutral on expectations, with lower—but not eliminated—closing risk. Nothing here changes the agreed economics or adds a competing bid; it confirms expected regulatory momentum while leaving the September 10 Australian waiting-period expiry and shareholder approval as remaining execution points. The filing therefore advances the transaction without creating a clean beat-versus-consensus signal.